Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free RNAC Stock Alerts

Cartesian Therapeutics (RNAC) Competitors

Cartesian Therapeutics logo
$8.74 +0.02 (+0.23%)
As of 03:25 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

RNAC vs. CVAC, OLMA, SANA, JANX, and OMER

Should you buy Cartesian Therapeutics stock or one of its competitors? Cartesian Therapeutics's main competitors and comparable companies include CureVac (CVAC), Olema Pharmaceuticals (OLMA), Sana Biotechnology (SANA), Janux Therapeutics (JANX), and Omeros (OMER). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Cartesian Therapeutics compare to CureVac?

Cartesian Therapeutics (NASDAQ:RNAC) and CureVac (NASDAQ:CVAC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

Cartesian Therapeutics presently has a consensus price target of $32.60, indicating a potential upside of 273.00%. Given Cartesian Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Cartesian Therapeutics is more favorable than CureVac.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cartesian Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57
CureVac
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

CureVac has a net margin of 199.92% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat CureVac's return on equity.

Company Net Margins Return on Equity Return on Assets
Cartesian Therapeutics-8,550.65% N/A -29.84%
CureVac 199.92%-23.03%-19.09%

87.0% of Cartesian Therapeutics shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 37.2% of Cartesian Therapeutics shares are owned by insiders. Comparatively, 2.2% of CureVac shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

CureVac has higher revenue and earnings than Cartesian Therapeutics. Cartesian Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cartesian Therapeutics$2.80M94.42-$130.30M-$5.94N/A
CureVac$70.74M14.78$175.50M$0.726.47

In the previous week, Cartesian Therapeutics had 15 more articles in the media than CureVac. MarketBeat recorded 15 mentions for Cartesian Therapeutics and 0 mentions for CureVac. Cartesian Therapeutics' average media sentiment score of 0.58 beat CureVac's score of 0.00 indicating that Cartesian Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Cartesian Therapeutics Positive
CureVac Neutral

Cartesian Therapeutics has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market. Comparatively, CureVac has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market.

Summary

Cartesian Therapeutics beats CureVac on 9 of the 16 factors compared between the two stocks.

How does Cartesian Therapeutics compare to Olema Pharmaceuticals?

Olema Pharmaceuticals (NASDAQ:OLMA) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.

Olema Pharmaceuticals currently has a consensus price target of $42.40, indicating a potential upside of 296.30%. Cartesian Therapeutics has a consensus price target of $32.60, indicating a potential upside of 273.00%. Given Olema Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Olema Pharmaceuticals is more favorable than Cartesian Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Olema Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.71
Cartesian Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

Olema Pharmaceuticals has a beta of 2.03, meaning that its share price is 103% more volatile than the broader market. Comparatively, Cartesian Therapeutics has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market.

In the previous week, Olema Pharmaceuticals had 10 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 25 mentions for Olema Pharmaceuticals and 15 mentions for Cartesian Therapeutics. Cartesian Therapeutics' average media sentiment score of 0.58 beat Olema Pharmaceuticals' score of -0.42 indicating that Cartesian Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Olema Pharmaceuticals
2 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
6 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cartesian Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

91.8% of Olema Pharmaceuticals shares are held by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are held by institutional investors. 12.6% of Olema Pharmaceuticals shares are held by company insiders. Comparatively, 37.2% of Cartesian Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Olema Pharmaceuticals has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat Olema Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Olema PharmaceuticalsN/A -48.50% -43.37%
Cartesian Therapeutics -8,550.65%N/A -29.84%

Cartesian Therapeutics has higher revenue and earnings than Olema Pharmaceuticals. Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Olema PharmaceuticalsN/AN/A-$162.45M-$2.12N/A
Cartesian Therapeutics$2.80M94.42-$130.30M-$5.94N/A

Summary

Olema Pharmaceuticals beats Cartesian Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Cartesian Therapeutics compare to Sana Biotechnology?

Sana Biotechnology (NASDAQ:SANA) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

Sana Biotechnology has a beta of 2.16, indicating that its share price is 116% more volatile than the broader market. Comparatively, Cartesian Therapeutics has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market.

Sana Biotechnology presently has a consensus target price of $9.33, indicating a potential upside of 165.53%. Cartesian Therapeutics has a consensus target price of $32.60, indicating a potential upside of 273.00%. Given Cartesian Therapeutics' higher possible upside, analysts clearly believe Cartesian Therapeutics is more favorable than Sana Biotechnology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sana Biotechnology
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.67
Cartesian Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

Sana Biotechnology has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat Sana Biotechnology's return on equity.

Company Net Margins Return on Equity Return on Assets
Sana BiotechnologyN/A -102.39% -39.71%
Cartesian Therapeutics -8,550.65%N/A -29.84%

Cartesian Therapeutics has higher revenue and earnings than Sana Biotechnology. Sana Biotechnology is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sana BiotechnologyN/AN/A-$244.17M-$0.76N/A
Cartesian Therapeutics$2.80M94.42-$130.30M-$5.94N/A

In the previous week, Sana Biotechnology had 3 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 18 mentions for Sana Biotechnology and 15 mentions for Cartesian Therapeutics. Cartesian Therapeutics' average media sentiment score of 0.58 beat Sana Biotechnology's score of 0.15 indicating that Cartesian Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sana Biotechnology
1 Very Positive mention(s)
3 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cartesian Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

88.2% of Sana Biotechnology shares are held by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are held by institutional investors. 25.4% of Sana Biotechnology shares are held by insiders. Comparatively, 37.2% of Cartesian Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Cartesian Therapeutics beats Sana Biotechnology on 8 of the 15 factors compared between the two stocks.

How does Cartesian Therapeutics compare to Janux Therapeutics?

Janux Therapeutics (NASDAQ:JANX) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

Janux Therapeutics has a beta of 2.5, indicating that its share price is 150% more volatile than the broader market. Comparatively, Cartesian Therapeutics has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market.

Janux Therapeutics presently has a consensus price target of $37.58, indicating a potential upside of 133.15%. Cartesian Therapeutics has a consensus price target of $32.60, indicating a potential upside of 273.00%. Given Cartesian Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cartesian Therapeutics is more favorable than Janux Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Janux Therapeutics
2 Sell rating(s)
3 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.50
Cartesian Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

Janux Therapeutics has higher revenue and earnings than Cartesian Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Janux Therapeutics$10M98.56-$113.62M-$1.64N/A
Cartesian Therapeutics$2.80M94.42-$130.30M-$5.94N/A

Janux Therapeutics has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat Janux Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Janux TherapeuticsN/A -11.89% -11.13%
Cartesian Therapeutics -8,550.65%N/A -29.84%

75.4% of Janux Therapeutics shares are held by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are held by institutional investors. 7.9% of Janux Therapeutics shares are held by company insiders. Comparatively, 37.2% of Cartesian Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Janux Therapeutics had 5 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 20 mentions for Janux Therapeutics and 15 mentions for Cartesian Therapeutics. Cartesian Therapeutics' average media sentiment score of 0.58 beat Janux Therapeutics' score of 0.43 indicating that Cartesian Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Janux Therapeutics
2 Very Positive mention(s)
4 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cartesian Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

Summary

Janux Therapeutics beats Cartesian Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Cartesian Therapeutics compare to Omeros?

Omeros (NASDAQ:OMER) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

Omeros has a beta of 2.54, meaning that its stock price is 154% more volatile than the broader market. Comparatively, Cartesian Therapeutics has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market.

Omeros presently has a consensus price target of $38.00, indicating a potential upside of 120.05%. Cartesian Therapeutics has a consensus price target of $32.60, indicating a potential upside of 273.00%. Given Cartesian Therapeutics' higher probable upside, analysts plainly believe Cartesian Therapeutics is more favorable than Omeros.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Omeros
0 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.67
Cartesian Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

Omeros has higher earnings, but lower revenue than Cartesian Therapeutics. Cartesian Therapeutics is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OmerosN/AN/A-$3.35M$0.7024.67
Cartesian Therapeutics$2.80M94.42-$130.30M-$5.94N/A

Omeros has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat Omeros' return on equity.

Company Net Margins Return on Equity Return on Assets
OmerosN/A -139.37% 70.79%
Cartesian Therapeutics -8,550.65%N/A -29.84%

48.8% of Omeros shares are owned by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are owned by institutional investors. 10.5% of Omeros shares are owned by company insiders. Comparatively, 37.2% of Cartesian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Omeros had 6 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 21 mentions for Omeros and 15 mentions for Cartesian Therapeutics. Omeros' average media sentiment score of 0.75 beat Cartesian Therapeutics' score of 0.58 indicating that Omeros is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Omeros
5 Very Positive mention(s)
1 Positive mention(s)
8 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Cartesian Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

Summary

Omeros beats Cartesian Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Cartesian Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RNAC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RNAC vs. The Competition

Export
MetricCartesian TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$264.14M$3.71B$6.99B$13.03B
Dividend YieldN/A3.76%2.58%10.72%
P/E Ratio-1.4710.52269.5525.26
Price / Sales94.421,290.58597.75101.23
Price / CashN/A103.0170.5350.75
Price / Book-2.1117.5013.086.33
Net Income-$130.30M-$13.32M$3.45B$347.70M
7 Day Performance-1.24%1.53%1.02%0.97%
1 Month Performance1.39%1.39%1.68%0.92%
1 Year Performance-23.53%55.83%67.42%20.45%

Cartesian Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RNAC
Cartesian Therapeutics
2.4095 of 5 stars		$8.74
+0.2%		$32.60
+273.0%		-25.5%$264.14M$2.80MN/A64
CVAC
CureVac
N/A$4.66
flat		N/AN/A$1.05B$70.74M6.47880
OLMA
Olema Pharmaceuticals
1.9765 of 5 stars		$10.43
-12.6%		$43.60
+318.0%		+98.9%$1.04BN/AN/A70
SANA
Sana Biotechnology
1.6762 of 5 stars		$3.79
+5.0%		$9.50
+150.7%		+10.7%$1.00BN/AN/A380
JANX
Janux Therapeutics
2.6943 of 5 stars		$16.52
+0.7%		$37.58
+127.5%		-35.9%$1.00B$10MN/A30

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:RNAC) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Buffett's Final Warning: "The Dollar Is Going to Hell"
The US just hit $39 trillion in debt. Interest alone is now over $1 trillion a year, more than the entire defe...
Decentralized Masters | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
Wall Street is staring at the wrong AI trade
Anthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...
The Oxford Club | Sponsoredtc pixel
After KDA, PRE, and OCEAN—this is the one
17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...
Crypto 101 Media | Sponsoredtc pixel